Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | NQO1 | P15559 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 4/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4839537 | 0.91 | GRN (0.36) | ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL4834842 | 0.86 | ALDH1A1 (0.46) | ALDH1A1KDM4EMEN1KMT2ANQO1 | |
| SCHEMBL6498155 | 0.86 | ALDH1A1 (0.46) | ALDH1A1KDM4EMEN1KMT2ANQO1 | |
| SCHEMBL6503499 | 0.85 | MAOB (0.35) | ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL6503503 | 0.85 | MAOB (0.35) | ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL6502750 | 0.82 | ALDH1A1 (0.46) | ALDH1A1MAOBNQO1 | |
| SCHEMBL8258089 | 0.78 | CTSS (0.44) | — | |
| SCHEMBL4828758 | 0.76 | ALDH1A1 (0.46) | ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL6658321 | 0.70 | CTSL (0.44) | — | |
| SCHEMBL5365086 | 0.69 | ALDH1A1 (0.47) | ALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1694357-A1 | USE OF CATHEPSIN S INHIBITORS FOR TREATING AN IMMUNE RESPONSE CAUSED BY ADMINISTRATION OF A SMALL MOLECULE THERAPEUTIC OR BIOLOGIC | AXYS PHARMACEUTICALS, INC. (US) | 2006-08-30 | — | — | EP | claimed |
| US-6936606-B2 | Cyanoamido-containing heterocyclic compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-08-30 | — | — | US | claimed |
| WO-2005058348-A1 | USE OF CATHEPSIN S INHIBITORS FOR TREATING AN IMMUNE RESPONSE CAUSED BY ADMINISTRATION OF A SMALL MOLECULE THERAPEUTIC OR BIOLOGIC | AXYS PHARMACEUTICALS, INC. (US) | 2005-06-30 | — | — | WO | claimed |
| EP-1434769-A2 | COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-07-07 | — | — | EP | claimed |
| US-20040063679-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | claimed |
| WO-2003029200-A2 | COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-04-10 | — | — | WO | claimed |
| US-7465745-B2 | Cathepsin S inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-7326719-B2 | Cathepsin S inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-02-05 | — | — | US | disclosed |
| EP-1694357-A1 | USE OF CATHEPSIN S INHIBITORS FOR TREATING AN IMMUNE RESPONSE CAUSED BY ADMINISTRATION OF A SMALL MOLECULE THERAPEUTIC OR BIOLOGIC | AXYS PHARMACEUTICALS, INC. (US) | 2006-08-30 | — | — | EP | disclosed |
| EP-1606258-A1 | CATHEPSIN S INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050222145-A1 | Cathepsin S inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-10-06 | — | — | US | disclosed |
| US-6936606-B2 | Cyanoamido-containing heterocyclic compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| WO-2005058348-A1 | USE OF CATHEPSIN S INHIBITORS FOR TREATING AN IMMUNE RESPONSE CAUSED BY ADMINISTRATION OF A SMALL MOLECULE THERAPEUTIC OR BIOLOGIC | AXYS PHARMACEUTICALS, INC. (US) | 2005-06-30 | — | — | WO | disclosed |
| WO-2004083182-A1 | CATHEPSIN S INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | WO | disclosed |
| US-20040180886-A1 | Cathepsin S inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-09-16 | — | — | US | disclosed |
| EP-1434769-A2 | COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20040063679-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2003029200-A2 | COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063679-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | ALDH1A1 2191/4885KDM4E 3708/4885SMN1; SMN2 4664/4885 |
| US-20040180886-A1 | Cathepsin S inhibitors | CTSS, CTSB, CTSZ | ALDH1A1 2916/4885KDM4E 3820/4885SMN1; SMN2 4126/4885 |
| US-20050222145-A1 | Cathepsin S inhibitors | CTSS, CTSB, CTSZ | ALDH1A1 3363/4885KDM4E 3761/4885SMN1; SMN2 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.